CytoDyn Completes Safety Testing of Cytolin(R): Benchmark for Improved Treatment of HIV/AIDS

SANTA FE, N.M.--(BUSINESS WIRE)--CytoDyn, Inc. (Pink Sheets:CYDY) has completed safety testing of its current inventory of Cytolin®, the Company’s immune-system modulator for managing HIV disease and the public health crisis afflicting communities where the infection is spreading due to unprotected sex and the other risk factors for AIDS. Tests for specific adventitious agents and other quality parameters following purification were performed by the manufacturing facility, Vista Biologicals Corporation of Carlsbad, California. The other safety tests, including in vivo general safety using two animal species, were performed by WuXi AppTec, a fully integrated pharmaceutical, biotechnology and medical-device company with facilities in St. Paul, Minnesota. WuXi AppTec provides R&D services to the biotechnology industry. Since the product is intended for use in a clinical trial, the tests conducted were those required for each new batch of a biologic agent manufactured for use in human research. The Company believes that the test results satisfy the current safety standards for the manufacturing of drugs belonging to the class of biologics. The results are summarized in the table below.